Evaluation of Insulin Lispro Pharmacokinetics and Pharmacodynamics Over 10 Days of Continuous Insulin Infusion in People With Type 1 Diabetes.

Garhyan, Parag; Pratt, Edward; Klein, Oliver; Famulla, Susanne; Zijlstra, Eric; Lalonde, Amy; Swinney, Monica; Kazda, Christof; Dassau, Eyal

Garhyan, Parag; Pratt, Edward; Klein, Oliver; Famulla, Susanne; Zijlstra, Eric; Lalonde, Amy; Swinney, Monica; Kazda, Christof; Dassau, Eyal.

Garhyan P; Eli Lilly and Company, Indianapolis, IN, USA.
Pratt E; Lilly Centre for Clinical Pharmacology, Singapore, Singapore.
Klein O; Profil, Neuss, Germany.
Famulla S; Profil, Neuss, Germany.
Zijlstra E; Profil, Neuss, Germany.
Lalonde A; Eli Lilly and Company, Indianapolis, IN, USA.
Swinney M; Eli Lilly and Company, Cambridge, MA, USA.
Kazda C; Eli Lilly and Company, Indianapolis, IN, USA.
Dassau E; Eli Lilly and Company, Indianapolis, IN, USA.

J Diabetes Sci Technol ; 17(2): 274-282, 2023 03.

Article en En | MEDLINE | ID: mdl-36575993

Asunto(s)

Diabetes Mellitus Tipo 1; Insulina; Adulto; Humanos; Insulina Lispro; Diabetes Mellitus Tipo 1/tratamiento farmacológico; Hipoglucemiantes; Estudios Cruzados; Meloxicam; Glucemia; Insulina Regular Humana

Palabras clave

LY900027; continuous subcutaneous insulin infusion; insulin lispro; pharmacodynamics; pharmacokinetics; type 1 diabetes

Texto completo

Imprimir

XML

PubMed Links

Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Diabetes Mellitus Tipo 1 / Insulina Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Search on Google